PharmaTher’s Ketamine Receives the US FDA’s Orphan Drug Designation for Complex Regional Pain Syndrome

Shots:

• The US FDA has granted ODD to the Ketamine for the treatment of complex regional pain syndrome (CRPS) which is a rare chronic pain and inflammatory condition following an injury to a limb
• The ODD follows the US FDA’s ODD of ketamine for the treatment of ALS, granted on Aug 04, 2021
• Ketamine acts as a noncompetitive, NMDA channel blocker that can prevent the induction of synaptic potentiation. The company is planning to initiate a P-II study of ketamine for CRPS in 2022

Click here to­ read full press release/ article | Ref: PharmaTher | Image: PharmaTher